BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1340 related articles for article (PubMed ID: 33161150)

  • 1. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis.
    Tleyjeh IM; Kashour Z; Damlaj M; Riaz M; Tlayjeh H; Altannir M; Altannir Y; Al-Tannir M; Tleyjeh R; Hassett L; Kashour T
    Clin Microbiol Infect; 2021 Feb; 27(2):215-227. PubMed ID: 33161150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.
    Tleyjeh IM; Kashour Z; Riaz M; Hassett L; Veiga VC; Kashour T
    Clin Microbiol Infect; 2021 Aug; 27(8):1076-1082. PubMed ID: 33915284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
    Ghosn L; Chaimani A; Evrenoglou T; Davidson M; Graña C; Schmucker C; Bollig C; Henschke N; Sguassero Y; Nejstgaard CH; Menon S; Nguyen TV; Ferrand G; Kapp P; Riveros C; Ávila C; Devane D; Meerpohl JJ; Rada G; Hróbjartsson A; Grasselli G; Tovey D; Ravaud P; Boutron I
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013881. PubMed ID: 33734435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Piechotta V; Iannizzi C; Chai KL; Valk SJ; Kimber C; Dorando E; Monsef I; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013600. PubMed ID: 34013969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remdesivir for the treatment of COVID-19.
    Ansems K; Grundeis F; Dahms K; Mikolajewska A; Thieme V; Piechotta V; Metzendorf MI; Stegemann M; Benstoem C; Fichtner F
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014962. PubMed ID: 34350582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project).
    Juul S; Nielsen EE; Feinberg J; Siddiqui F; Jørgensen CK; Barot E; Holgersson J; Nielsen N; Bentzer P; Veroniki AA; Thabane L; Bu F; Klingenberg S; Gluud C; Jakobsen JC
    PLoS One; 2021; 16(3):e0248132. PubMed ID: 33705495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ivermectin for preventing and treating COVID-19.
    Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic corticosteroids for the treatment of COVID-19.
    Wagner C; Griesel M; Mikolajewska A; Mueller A; Nothacker M; Kley K; Metzendorf MI; Fischer AL; Kopp M; Stegemann M; Skoetz N; Fichtner F
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014963. PubMed ID: 34396514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-1 blocking agents for treating COVID-19.
    Davidson M; Menon S; Chaimani A; Evrenoglou T; Ghosn L; Graña C; Henschke N; Cogo E; Villanueva G; Ferrand G; Riveros C; Bonnet H; Kapp P; Moran C; Devane D; Meerpohl JJ; Rada G; Hróbjartsson A; Grasselli G; Tovey D; Ravaud P; Boutron I
    Cochrane Database Syst Rev; 2022 Jan; 1(1):CD015308. PubMed ID: 35080773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID-19; a systematic review and meta-analysis of randomized clinical trials.
    Vela D; Vela-Gaxha Z; Rexhepi M; Olloni R; Hyseni V; Nallbani R
    Br J Clin Pharmacol; 2022 May; 88(5):1955-1963. PubMed ID: 34713921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Piechotta V; Chai KL; Valk SJ; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD013600. PubMed ID: 32648959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled corticosteroids for the treatment of COVID-19.
    Griesel M; Wagner C; Mikolajewska A; Stegemann M; Fichtner F; Metzendorf MI; Nair AA; Daniel J; Fischer AL; Skoetz N
    Cochrane Database Syst Rev; 2022 Mar; 3(3):CD015125. PubMed ID: 35262185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis.
    Kyriakopoulos C; Ntritsos G; Gogali A; Milionis H; Evangelou E; Kostikas K
    Respirology; 2021 Nov; 26(11):1027-1040. PubMed ID: 34605114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis.
    Kim MS; An MH; Kim WJ; Hwang TH
    PLoS Med; 2020 Dec; 17(12):e1003501. PubMed ID: 33378357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
    Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013825. PubMed ID: 34473343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial.
    Soin AS; Kumar K; Choudhary NS; Sharma P; Mehta Y; Kataria S; Govil D; Deswal V; Chaudhry D; Singh PK; Gupta A; Agarwal V; Kumar S; Sangle SA; Chawla R; Narreddy S; Pandit R; Mishra V; Goel M; Ramanan AV
    Lancet Respir Med; 2021 May; 9(5):511-521. PubMed ID: 33676589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
    Stroehlein JK; Wallqvist J; Iannizzi C; Mikolajewska A; Metzendorf MI; Benstoem C; Meybohm P; Becker M; Skoetz N; Stegemann M; Piechotta V
    Cochrane Database Syst Rev; 2021 May; 5(5):CD015043. PubMed ID: 34029377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.